Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Verrica Pharmaceuticals Inc
Gross Profit
Verrica Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
|
Gross Profit
$4.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$61.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$36.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$47.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$51.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$36.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
Verrica Pharmaceuticals Inc
Glance View
Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.
See Also
What is Verrica Pharmaceuticals Inc's Gross Profit?
Gross Profit
4.8m
USD
Based on the financial report for Dec 31, 2024, Verrica Pharmaceuticals Inc's Gross Profit amounts to 4.8m USD.
What is Verrica Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 1Y
10%
Over the last year, the Gross Profit growth was 10%.
You don't have any saved screeners yet